GLP-1 plus therapy can reduce heavy drinking
May 12, 2026 At a Glance People with alcohol use disorder and obesity drank less when treated with…
Ozempic users face more stigma than people who don’t lose weight: study
In the Ozempic era, not all pounds lost are met with praise. New research suggests that people may…
Weight-Loss Drugs Like Ozempic May Come With an Unexpected Cost
Glucagon-like peptide-1 (GLP-1) medications are drugs used to treat type 2 diabetes and support weight loss. They mimic…
Is Loving Food the Secret to Eating Less of It?
“So much of the wellness conversation is about self-denial,” said Dr. Emanuel, a bioethicist and oncologist at the…
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
Animals and housing conditions Experiments were performed in accordance with the Animal Protection Law of the European Union…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with…
Liver Talks to the Brain to Control Appetite
Summary: Researchers mapped a critical neural pathway that regulates how the body responds to dietary changes. The study…
Bread Might Be Making You Gain Weight Even Without Eating More Calories
In a new study, mice strongly preferred foods like bread, rice, and wheat, abandoning their regular diet and…
Why Popular Diabetes Drugs Like Ozempic Don’t Work for Everyone: The “Genetic Glitch”
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro were developed for Type 2 diabetes but are now also used…
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
A recent study from the University of North Carolina School of Medicine found that weight loss, especially from…
Eating oranges daily may shift lipid patterns in fatty liver disease
A 4-week clinical trial explores whether everyday oranges can subtly influence lipid metabolism in fatty liver disease, revealing…
LLY’s Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
Eli Lilly and Company LLY announced that a phase III study, ACHIEVE-4, evaluating its newly approved oral GLP-1…